(Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

The recent trial regarding the discontinued heartburn drug Zantac, which allegedly causes cancer, ended in a hung jury. The ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...

This summary presents key updates in the health sector. Highlights include UnitedHealth's tech unit customers adopting ...